Natalie Cook

List of Publications by Citations

43 papers	3,972 citations	22 h-index	46 g-index
46 ext. papers	4,588 ext. citations	9.2 avg, IF	4.9 L-index

#	Paper	IF	Citations
43	The pancreas cancer microenvironment. *Clinical Cancer Research*, **2012**, 18, 4266-76	12.9	863
42	Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. *Gut*, **2013**, 62, 112-20	19.2	690
41	Stromal biology and therapy in pancreatic cancer. *Gut*, **2011**, 60, 861-8	19.2	532
40	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncology, The*, **2014**, 15, 78-86	21.7	413
39	nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. *Cancer Discovery*, **2012**, 2, 260-269	24.4	309
38	Crosstalk between the canonical NF-B and Notch signaling pathways inhibits Ppar expression and promotes pancreatic cancer progression in mice. *Journal of Clinical Investigation*, **2011**, 121, 4685-99	15.9	184
37	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. *Nature Medicine*, **2019**, 25, 738-743	50.5	119
36	Predictive in vivo animal models and translation to clinical trials. *Drug Discovery Today*, **2012**, 17, 253-60	8.8	80
35	Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. *BJU International*, **2009**, 103, 747-52	5.6	79
34	Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. *Journal of Experimental Medicine*, **2012**, 209, 437-44	16.6	78
33	Early phase clinical trials to identify optimal dosing and safety. *Molecular Oncology*, **2015**, 9, 997-1007	7.9	59
32	A phase I trial of the secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. *British Journal of Cancer*, **2018**, 118, 793-801	8.7	55
31	Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. *Gut*, **2012**, 61, 877-84	19.2	54
30	Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. *British Journal of Cancer*, **2016**, 114, 381-7	8.7	47
29	Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. *Pancreatology*, **2012**, 12, 8-15	3.8	46
28	Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'. *British Journal of Cancer*, **2019**, 120, 141-153	8.7	45
27	A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. *Cancer Chemotherapy and Pharmacology*, **2011**, 68, 1243-53	3.5	42

26	FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. *British Journal of Cancer*, **2016**, 115, 649-54	8.7	35
25	Exome-Wide Association Study of Pancreatic Cancer Risk. *Gastroenterology*, **2018**, 154, 719-722.e3	13.3	27
24	K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. *Methods in Enzymology*, **2008**, 439, 73-85	1.7	26
23	Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. *PLoS ONE*, **2013**, 8, e67330	3.7	24
22	A phase 2 study of vatalanib in metastatic melanoma patients. *European Journal of Cancer*, **2010**, 46, 2671-3	7.5	23
21	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. *Oncologist*, **2015**, 20, 653-9	5.7	18
20	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. *Nature Medicine*, **2021**, 27, 793-801	50.5	18
19	Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma. *Journal of Clinical Pathology*, **2015**, 68, 309-13	3.9	16
18	Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. *Ecological Management and Restoration*, **2015**, 28, 612-8	3	16
17	Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. *British Journal of Cancer*, **2014**, 111, 318-25	8.7	16
16	A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer. *Statistics in Medicine*, **2012**, 31, 1931-43	2.3	12
15	E-Mail Communication Practices and Preferences Among Patients and Providers in a Large Comprehensive Cancer Center. *Journal of Oncology Practice*, **2016**, 12, 676-84	3.1	11
14	Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin. *Npj Genomic Medicine*, **2018**, 3, 15	6.2	8
13	TARGET trial: Molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials.. *Journal of Clinical Oncology*, **2016**, 34, TPS11614-TPS11614	2.2	5
12	Determinants of the recommended phase 2 dose of molecular targeted agents. *Cancer*, **2017**, 123, 1409-1415	6.4	4
11	Challenge of the Unknown: How Can We Improve Clinical Outcomes in Cancer of Unknown Primary?. *Journal of Clinical Oncology*, **2019**, 37, 2089-2090	2.2	4
10	Drug development and clinical trial design in pancreatico-biliary malignancies. *Current Problems in Cancer*, **2018**, 42, 73-94	2.3	4
9	The International Core Literature Consensus (ICLC): an alternative curriculum for Oncologists. *Journal of Cancer Education*, **2011**, 26, 420-6	1.8	3

8	Novel Early Phase Clinical Trial Design in Oncology. *Pharmaceutical Medicine*, **2017**, 31, 297-307	2.3	2
7	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. *British Journal of Cancer*, **2021**, 124, 391-398	8.7	2
6	FOLFIRINOX for advanced pancreatic cancer: The Princess Margaret experience.. *Journal of Clinical Oncology*, **2015**, 33, 417-417	2.2	1
5	Integration of early supportive and palliative care in a patient journey with cancer. *Progress in Palliative Care*, **2019**, 27, 206-212	1	
4	Reply to K.K. Sahu et al. *Journal of Oncology Practice*, **2017**, 13, 215	3.1	
3	How to Design Phase I Trials in Oncology **2018**, 165-187		
2	Email communication practices and preferences among patients and providers in a large comprehensive cancer center.. *Journal of Clinical Oncology*, **2015**, 33, 6519-6519	2.2	
1	Developing a CAncer genomics Digital Educational Tool to assess the knowledge and expectations of patients with advanced solid tumors (CADET).. *Journal of Clinical Oncology*, **2015**, 33, 6524-6524	2.2	